Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of a panel of biomarkers in the preparation of a kit for predicting the progression of intravenous leiomyomatosis

A biomarker and leiomyoma technology, applied in the application field of the kit, can solve the problems of metabolite changes in unconcerned patients, judge IVL, etc., and achieve good clinical value, high accuracy, and strong operability

Active Publication Date: 2022-07-15
PEKING UNION MEDICAL COLLEGE HOSPITAL CHINESE ACAD OF MEDICAL SCI
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, most studies only explore the potential regulatory genes that affect the pathogenesis and prognosis of IVL, and do not pay attention to the changes of a series of metabolites in patients
Therefore, there are currently no specific biochemical indicators to judge the diagnosis and prognosis of IVL.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of a panel of biomarkers in the preparation of a kit for predicting the progression of intravenous leiomyomatosis
  • Application of a panel of biomarkers in the preparation of a kit for predicting the progression of intravenous leiomyomatosis
  • Application of a panel of biomarkers in the preparation of a kit for predicting the progression of intravenous leiomyomatosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] The term IVL used in the present invention is the English abbreviation of intravenous leiomyomato-sis.

[0036] 1. Sample collection

[0037] This study complied with the Declaration of Helsinki and the Guidelines for the Coordination of Clinical Practice and was approved by the Ethics Committee of Peking Union Medical College Hospital (Ethics: JS-2654). All study participants signed informed consent. The disease group in this study included IVL patients who underwent surgery at Peking Union Medical College Hospital from December 2011 to May 2020 and were followed up regularly. The study population was divided into two groups: 30 healthy controls were in the Co group, half of whom had no uterine fibroids (Co-no) and the rest were uterine fibroids (Co-um); 30 IVL patients were further treated according to postoperative recurrence. Divided into no recurrence group (IVL-no) and recurrence group (IVL-re). There were 15 samples in each of the above four subgroups.

[003...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
Login to View More

Abstract

The invention discloses the application of a set of biomarkers in the preparation of a kit for predicting the progression of intravenous leiomyomatosis, the biomarkers are hypoxanthine, glycerophosphocholine, acetylcarnitine, hydrocortisone ( Cortisol), the expression levels of the biomarkers hypoxanthine and glycerophosphocholine decreased with disease progression, and the expression levels of acetylcarnitine and hydrocortisone (cortisol) increased with disease progression. The invention also discloses a method for screening biomarkers for predicting the progression of venous leiomyomatosis. Using the biomarker hypoxanthine, glycerophosphocholine, acetylcarnitine and hydrocortisone (cortisol) of the present invention to predict the progression of venous leiomyomatosis has high specificity and is beneficial to venous leiomyoma Early detection and early treatment of the disease have good clinical use and promotion value.

Description

technical field [0001] The invention relates to the field of biological detection, in particular to the application of a set of biological markers in the preparation of a kit for predicting the progression of intravenous leiomyomatosis. Background technique [0002] Intravenous leiomyomatosis (IVL) is a rare estrogen-dependent neoplastic disease. Although IVL is histologically benign, it is characterized by invasive growth. Tumors originate from the uterine venous wall or pelvic veins, which can extend into the venous passages of the uterus or pelvis, invade through the iliac or ovarian veins, and extend to the inferior vena cava. Once the tumor enters the right atrium or right ventricle and pulmonary artery through the tricuspid valve, it can cause severe circulatory disturbances that can lead to syncope or sudden death. If part of the tumor in the heart breaks off, it can lead to a pulmonary embolism or cerebral infarction, which can be life-threatening. Due to the uncl...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): G01N30/02G01N30/72G01N30/86
CPCG01N30/02G01N30/72G01N30/8631
Inventor 葛志通冯鹏辉李建初张紫娟郁琦
Owner PEKING UNION MEDICAL COLLEGE HOSPITAL CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products